Accessibility and accommodation Novartis is committed to working with and providing reasonable accommodation to individuals with disabilities. If, because of a medical condition or disability, you ...

主要职责：保证每月拜访规定数量的目标客户和组织产品学术推广会，配合公司大型学术活动建立完善的客户管理体系，提高客户服务质量及时、准确执行报告系统，及时汇报工作的进展，及时反馈市场信息配合地区经理的协同拜访完成地区经理或者大区经理指派的工作任务积极参与和推进合规项目 ...

Novartis ricerca costantemente nuovi talenti da inserire nel proprio organico. Visualizza le opportunità di impiego nelle diverse Divisioni e in tutti i paesi.

Audit & Finance BD&L & Strategic Planning Commercial & General Management Communications & Public Affairs Data and Digital Facilities & Administration Human Resources Information Technology ...

As Chief Audit Officer of Novartis, Teresa and her team provide risk-based assurance and advice on key strategic topics to the Board and management, acting as a key partner to the organization to help ...

V Novartisu přetváříme medicínu Jsme globální farmaceutickou společností, která působí ve 140 zemích světa a zaměstnává přibližně 110 tisíc lidí. Naším posláním je objevovat nová řešení, které ...

We are excited to welcome the talented team at Regulus to Novartis as we continue to build on our pipeline in renal disease with high unmet medical need.” Farabursen is an investigational ...

Novartis works with the patient community around the world to discover new ways to improve and extend people’s lives. Novartis works closely with healthcare professionals around the world to support ...

Modern Slavery Statement 2024 - Australia, Canada, and United Kingdom (PDF 0.3 MB) Our statement under UK, Canadian and Australian legislation on our efforts to address modern slavery. Norwegian ...

Product portfolio At Novartis, we reimagine medicine to improve and extend people’s lives. This includes discovering and developing breakthrough therapies and finding new ways to deliver these ...

The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel (administered once following lymphodepletion) versus Standard of Care (SOC) in patients with systemic lupus ...

This is a Phase 3, parallel group, placebo-controlled, double-blind, confirmatory study in patients with CINDU, with an optional Open-label Extension (OLE). The purpose of the core period (52 weeks of ...